Clinical Trial Search

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Number of Participants With Treatment Success — 23 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin

Primary: To Evaluate Progression-free Survival of Paclitaxel/Carboplatin and Pembrolizumab in Patients With Advanced Stage, Metastatic Ovarian Cancer Undergoing NACT — 14.2 months

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants

Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants

Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065

Primary: Overall Response Rate — .083 proportion of participants

Primary: Maximum Tolerated Dose (MTD) — 105 mg/m^2

Primary: Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR) — 2.5; 0; 15; 40 Percentage of Participants

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants

Primary: Progression-free Survival — 2.6; 2.9 months

Primary: PFS — 29.8 Months

Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants

Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants